You searched for side effects - Page 35 of 311

Can teneligliptin be safely and effectively given to patients with inadequately controlled type 2 diabetes by triple oral antidiabetic drug treatment?

Posted by Medivizor on Sep 11, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and safety of teneligliptin (Tenelia) to placebo in patients with type 2 diabetes (T2D) that was inadequately controlled with triple oral antidiabetic drugs (OADs). The study showed that teneligliptin may be considered as a fourth add-on OAD treatment in these patients. Some background T2D is...

Evaluating the effectiveness and safety of opicapone for the treatment of non-motor symptoms in patients with Parkinson’s disease.

Posted by Medivizor on Sep 1, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of opicapone (Ongentys) for the treatment of non-motor symptoms in patients with Parkinson's disease (PD). The data showed that opicapone improved the non-motor symptoms and quality of life (QoL) with manageable side effects in patients with PD. Some background Parkinson's disease...

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Posted by Medivizor on Sep 1, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health...

Evaluating the effectiveness and safety of sugemalimab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Posted by Medivizor on Sep 1, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sugemalimab (Cejemly) after treatment with concurrent or sequential chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The data showed that sugemalimab significantly increased the survival without cancer worsening with manageable...

Can a combination of tamsulosin and herbal medicine improve lower urinary tract symptoms due to benign prostatic hyperplasia?

Posted by Medivizor on Aug 26, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study assessed the effectiveness and safety of combined therapy of tamsulosin (Flomax) and two different traditional herbal medicines in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study showed that tamsulosin with Ryutanshakanto provided pain relief in patients with chronic...

Evaluating the effectiveness, durability, and safety of faricimab in patients with diabetic macular edema.

Posted by Medivizor on Jul 16, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness, durability, and safety of faricimab (Vabysmo) for the treatment of patients with diabetic macular edema (DME). The data showed that faricimab with extended dosing up to every 16 weeks was safe and showed good vision gains and clinical improvements in these patients. Some background...

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by Medivizor on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Jun 26, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Posted by Medivizor on Jun 5, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

$Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma$

Posted by Medivizor on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

Can teneligliptin be safely and effectively given to patients with inadequately controlled type 2 diabetes by triple oral antidiabetic drug treatment?

Evaluating the effectiveness and safety of opicapone for the treatment of non-motor symptoms in patients with Parkinson’s disease.

Evaluating depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormone therapy

Evaluating the effectiveness and safety of sugemalimab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Can a combination of tamsulosin and herbal medicine improve lower urinary tract symptoms due to benign prostatic hyperplasia?

Evaluating the effectiveness, durability, and safety of faricimab in patients with diabetic macular edema.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email